MET Stock Analysis: MetLife | NYSE

Insurance - Life | NYSE, USA | Market Cap: 64.510m USD | 12M Return: 38% | US59156R1086 | Charts, Fundamentals & Technical Analysis

Life Insurance, Annuities, Group Benefits, Asset Management
Total Rating 61
Safety 72
Buy Signal 0.47
Life & Health Insurance
Sub-Industry Rotation: +5.2
Market Cap: 64.5B
Avg Turnover: 305M
Risk 3d forecast
Volatility23.1%
VaR 5th Pctl4.15%
VaR vs Median9.03%
Reward TTM
Sharpe Ratio1.33
Rel. Str. IBD86.7
Rel. Str. Peer Group77.5 pctl
Character TTM
Beta0.494
Beta Downside0.416
Hurst Exponent0.465
Choppyness51.7%
Drawdowns 3y
Max DD21.97%
CAGR/Max DD0.97
CAGR/Mean DD3.79
EPS (Earnings per Share) EPS (Earnings per Share) of MET over the last years for every Quarter: "2021-09": 2.39, "2021-12": 2.17, "2022-03": 2.08, "2022-06": 2, "2022-09": 1.21, "2022-12": 1.55, "2023-03": 1.52, "2023-06": 1.94, "2023-09": 1.97, "2023-12": 1.83, "2024-03": 1.83, "2024-06": 2.28, "2024-09": 1.95, "2024-12": 2.09, "2025-03": 1.96, "2025-06": 2.02, "2025-09": 2.34, "2025-12": 2.49, "2026-03": 2.42, "2026-06": 2.43, "2026-09": 2.85,
EPS CAGR: 11.32%
EPS Trend: 95.7%
Last SUE: 1.00
Qual. Beats: 4
Revenue Revenue of MET over the last years for every Quarter: 2021-09: 16905, 2021-12: 20089, 2022-03: 15756, 2022-06: 15556, 2022-09: 22270, 2022-12: 16316, 2023-03: 15388, 2023-06: 16623, 2023-09: 15866, 2023-12: 19028, 2024-03: 15902, 2024-06: 17491, 2024-09: 18298, 2024-12: 18440, 2025-03: 18263, 2025-06: 17176, 2025-09: 16881, 2025-12: 23814, 2026-03: 19074, 2026-06: 18877, 2026-09: 20522,
Rev. CAGR: 7.08%
Rev. Trend: 95.1%
Last SUE: 0.20
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

Rs Leader
Confidence

Seasonality 11.9 years of data, until 10/2026

Jan -0.1% 0
Feb -1.6% 47
Mar -0.9% 4
Apr +1.3% 14
May +0.0% 0
Jun +0.5% 0
Jul +1.4% 4
Aug -0.2% 0
Sep -1.0% 0
Oct -0.4% 0
Nov +5.7% 39
Dec -2.6% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: MET MetLife

MetLife, Inc. (NYSE: MET) is a global financial services company headquartered in New York, New York, incorporated in 1999 and publicly listed since its IPO on April 5, 2000. With a market capitalization of approximately $60.9 billion, it is classified as a large-cap stock within the GICS Financials sector, specifically in the Life & Health Insurance sub-industry.

The company operates through six reportable segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa (EMEA); and MetLife Holdings. Its broad product portfolio spans insurance (life, dental, disability, accident and health, vision, pet, and credit insurance), annuities (fixed, indexed-linked, and variable), employee benefits, and asset management services offered to both individual and institutional clients worldwide.

MetLife also provides specialized institutional offerings such as pension risk transfers, structured settlements, longevity reinsurance solutions, and capital markets investment products. Its diversified revenue base spans both retail and institutional markets across the Americas, Europe, and Asia, reflecting the scale typical of top-tier global life insurers that distribute products through employer-sponsored group plans, bancassurance partnerships, and direct sales channels.

Headlines to Watch Out For
  • Higher rates lift investment income across annuity and insurance liabilities
  • Asia premiums accelerate on Japan and emerging market demand
  • Pension risk transfer deals drive Retirement segment fee growth
Piotroski VR-10 (Strict) 6.0
Net Income: 5.13b TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.05 > 1.0
NWC/Revenue: 295.8% < 20% (prev -150.4%; Δ 446.2% < -1%)
CFO/TA 0.02 > 3% & CFO 15.0b > Net Income 5.13b
Net Debt (-22.2b) to EBITDA (7.90b): -2.81 < 3
Current Ratio: 2.29 > 1.5 & < 3
Outstanding Shares: last quarter (639.9m) vs 12m ago -4.36% < -2%
Gross Margin: 29.23% > 18% (prev 24.11%; Δ 5.12% > 0.5%)
Asset Turnover: 11.24% > 50% (prev 9.83%; Δ 1.41% > 0%)
Interest Coverage Ratio: 6.43 > 6 (EBIT TTM 7.15b / Interest Expense TTM 1.11b)
Altman Z'' 2.45
A: 0.33 (Total Current Assets 432b - Total Current Liabilities 189b) / Total Assets 745b
B: 0.06 (Retained Earnings 47.4b / Total Assets 745b)
C: 0.01 (EBIT TTM 7.15b / Avg Total Assets 732b)
D: 0.03 (Book Value of Equity 22.2b / Total Liabilities 722b)
Altman-Z'' = 2.45 = A
Beneish M -3.29
DSRI: 1.06 (Receivables 55.6b/45.3b, Revenue 82.3b/70.8b)
GMI: 0.82 (GM 24.11% / 29.23%)
AQI: 0.55 (AQ_t 0.42 / AQ_t-1 0.77)
SGI: 1.16 (Revenue 82.3b / 70.8b)
TATA: -0.01 (NI 5.13b - CFO 15.0b) / TA 745b)
Beneish M = -3.29 (Cap -4..+1) = AA
What is the price of MET shares?

As of November 18, 2026, the stock is trading at USD 101.50 with a total of 4,576,089 shares traded. Over the past week, the price has changed by -0.92%, over one month by +2.53%, over three months by +5.61% and over the past year by +38.04%.

Current recommended Stop Loss: 96.40 (which is 5% or 2.1 ATR below the current price).

Is MET a buy, sell or hold?

MetLife has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy MET.

  • StrongBuy: 8
  • Buy: 5
  • Hold: 4
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the MET price?
Analysts Target Price 110.9 9.3%
MetLife (MET) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 64.5b (64.5b USD * 1.0 USD.USD)
P/E Trailing = 13.4183
P/E Forward = 11.274
P/S = 0.7814
P/B = 2.9024
P/EG = 0.5423
Revenue TTM = 82.3b USD
EBIT TTM = 7.15b USD
EBITDA TTM = 7.90b USD
Long Term Debt = 21.4b USD (from longTermDebt, last quarter)
Short Term Debt = 289.0m USD (from shortTermDebt, last quarter)
Debt = 21.7b USD (from shortLongTermDebtTotal, last quarter) + Leases 6.00m
Net Debt = -22.2b USD (calculated: Debt 21.7b - CCE 43.9b)
Enterprise Value = 42.3b USD (64.5b + Debt 21.7b - CCE 43.9b)
Interest Coverage Ratio = 6.43 (Ebit TTM 7.15b / Interest Expense TTM 1.11b)
EV/FCF = 8.22x (Enterprise Value 42.3b / FCF TTM 5.14b)
FCF Yield = 12.16% (FCF TTM 5.14b / Enterprise Value 42.3b)
FCF Margin = 6.25% (FCF TTM 5.14b / Revenue TTM 82.3b)
Net Margin = 6.23% (Net Income TTM 5.13b / Revenue TTM 82.3b)
Gross Margin = 29.23% ((Revenue TTM 82.3b - Cost of Revenue TTM 58.2b) / Revenue TTM)
Gross Margin QoQ = 33.59% (prev 14.76%)
Tobins Q-Ratio = 0.06 (Enterprise Value 42.3b / Total Assets 745b)
Interest Expense / Debt = 5.12% (Interest Expense 1.11b / Debt 21.7b)
Taxrate = 22.38% (1.49b / 6.66b)
NOPAT = 5.55b (EBIT 7.15b * (1 - 22.38%))
Current Ratio = 2.10 (Total Current Assets 432b / Total Current Liabilities 206b)
Debt / Equity = 0.98 (Debt 21.7b / totalStockholderEquity, last quarter 22.2b)
Debt / EBITDA = -2.81 (Net Debt -22.2b / EBITDA 7.90b)
Debt / FCF = -4.32 (Net Debt -22.2b / FCF TTM 5.14b)
Total Stockholder Equity = 26.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.70% (Net Income 5.13b / Total Assets 745b)
RoE = 19.46% (Net Income TTM 5.13b / Total Stockholder Equity 26.3b)
RoCE = 14.97% (EBIT 7.15b / Capital Employed (Equity 26.3b + L.T.Debt 21.4b))
RoIC = 1.01% (NOPAT 5.55b / Invested Capital 552b)
WACC = 6.47% (E(64.5b)/V(86.2b) * Re(7.31%) + D(21.7b)/V(86.2b) * Rd(5.12%) * (1-Tc(0.22)))
Discount Rate = 7.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.01 | Cagr: -4.79%
[DCF] Terminal Value 76.77% ; FCFF base≈4.94b ; Y1≈5.41b ; Y5≈6.82b
[DCF] Fair Price = 201.2 (EV 104b - Net Debt -22.2b = Equity 126b / Shares 628.4m; r=8.35% [WACC [floored]]; 5y FCF grow 11.01% → 2.50% )
EPS Correlation: 95.66 | EPS CAGR: 11.32% | SUE: 1.00 | # QB: 4
Revenue Correlation: 95.10 | Revenue CAGR: 7.08% | SUE: 0.20 | # QB: 0
EPS current Quarter (2027-03-31): EPS=2.58 | Chg30d=-0.22% | Revisions=+57% | Analysts=11
EPS current Year (2026-12-31): EPS=10.23 | Chg30d=+0.38% | Revisions=+50% | GrowthEPS=+15.9% | GrowthRev=+0.8%
EPS next Year (2027-12-31): EPS=11.18 | Chg30d=+0.22% | Revisions=+36% | GrowthEPS=+9.3% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +58% (up=19, down=4)